机译:Statistical Considerations for Testing Multiple Endpoints in Group Sequential or Adaptive Clinical Trials
Division of Biometrics I, OB/OTS/CDER, FDA, Silver Spring, Maryland, USA;
Office of Biostatistics, OTS/CDER, FDA, Silver Spring, Maryland, USA;
Adaptive design; Closed testing; Flexible design; Group sequential; Primary endpoint; Secondary endpoint;